Spectral Medical (EDT) Stock Price, News & Analysis

Company Overview

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

Key Stats

• Today's Range: C$1.17 to C$1.17
• 50-Day Range: C$1.09 to C$1.41
• 52-Week Range: C$1.03 to C$1.65
• Volume: 6,420 shs
• Average Volume: 52,643 shs
• Market Capitalization: C$343.46 million
• P/E Ratio: N/A
• Dividend Yield: 1.45%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: TSE:EDT
• Previous Symbol: TSE:SDI
• CIK: N/A
• Web: www.spectraldx.com
• Phone: +1-416-6263233
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$18.68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -973.97%
• Return on Assets: -93.22%

Debt

• Debt-to-Equity Ratio: 26.03
• Current Ratio: 0.61
• Quick Ratio: 0.45

Sales & Book Value

• Annual Sales: C$2.57 million
• Price / Sales: 133.69
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 82.50
• Book Value: C($0.08) per share
• Price / Book: -14.63

Miscellaneous

• Outstanding Shares: 293,554,000
• Free Float: N/A
• Market Cap: C$343.46 million
• Optionable: Not Optionable
• Beta: 0.94